Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biorestorative Therapies Inc (BRTX)

Biorestorative Therapies Inc (BRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,548
  • Shares Outstanding, K 25,478
  • Annual Sales, $ 360 K
  • Annual Income, $ -14,240 K
  • EBIT $ -16 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.37
  • Price/Sales 18.40
  • Price/Cash Flow N/A
  • Price/Book 6.73
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.61
  • Most Recent Earnings $-0.37 on 03/26/26
  • Next Earnings Date 05/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 1
  • High Estimate $-0.30
  • Low Estimate $-0.30
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) +46.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2235 +16.15%
on 03/19/26
0.3300 -21.33%
on 03/23/26
+0.0074 (+2.93%)
since 03/17/26
3-Month
0.1900 +36.63%
on 02/23/26
1.1938 -78.25%
on 01/23/26
-0.8904 (-77.43%)
since 01/16/26
52-Week
0.1900 +36.63%
on 02/23/26
2.0450 -87.31%
on 06/12/25
-1.4904 (-85.17%)
since 04/17/25

Most Recent Stories

More News
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026...

BRTX : 0.2607 (+1.44%)
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales  No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...

BRTX : 0.2607 (+1.44%)
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th...

BRTX : 0.2607 (+1.44%)
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative...

BRTX : 0.2607 (+1.44%)
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues...

BRTX : 0.2607 (+1.44%)
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks.  BioRestorative believes its cell-based therapeutic...

BRTX : 0.2607 (+1.44%)
BioRestorative Announces Closing of $5.0 Million Public Offering

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator...

BRTX : 0.2607 (+1.44%)
BioRestorative Announces Pricing of $5.0 Million Public Offering

MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator...

BRTX : 0.2607 (+1.44%)
BioRestorative Announces Positive Outcome from Type B Meeting with FDA

BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated...

BRTX : 0.2607 (+1.44%)
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or...

BRTX : 0.2607 (+1.44%)

Business Summary

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM)...

See More

Key Turning Points

3rd Resistance Point 0.2764
2nd Resistance Point 0.2683
1st Resistance Point 0.2627
Last Price 0.2607
1st Support Level 0.2490
2nd Support Level 0.2409
3rd Support Level 0.2353

See More

52-Week High 2.0450
Fibonacci 61.8% 1.3364
Fibonacci 50% 1.1175
Fibonacci 38.2% 0.8986
Last Price 0.2607
52-Week Low 0.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.